en · de · es · fr · pt
melanotan-2-notes.peptides6579.com › Faq › Origins And Research Status — Reference Sheet

Origins And Research Status — Reference Sheet

By Editorial Desk · published 2025-07-02 · last reviewed 2025-07-18 · Faq

certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-07-18. Where a claim depends on a specific study, the study is described rather than over-claimed.

Origins and Research Status

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Quality Control and Analytical Practice

Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.

Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.

Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideBelongs to the melanocortin agonist family
Key substitutionsNle4 and D-Phe7Improve resistance to enzymatic degradation
Molecular formulaC50H69N15O9Approximately 1024 g/mol
Regulatory statusNot approved as a medicineDistributed as a research chemical
Common synonymsMelanotan II, MT-II, MT-2Spelling varies across sources

Melanotan-2 Identity And Regulatory Status

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Related pages on this site

Handling, Stability and Regulatory Status

Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.

Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.

Melanotan-2 Structure and Receptor Pharmacology

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Regulatory Status and Literature Discussion

Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.

Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.

Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.

Reference notes

=== Surgery === The surgery to repair the anterior vaginal wall may be combined with other procedures that will repair the other points of pelvic organ support such as anterior-posterior repair and anterior colporrhaphy. Treatment of cystocele often accompanies the more invasive hysterectomy. Since the failure rate in cystocele repair remains high, additional surgery may be needed. Women who have surgery to repair a cystocele have a 17% chance of needing another operation within the next ten years. The surgical treatment of cystocele will depend on the cause of the defect and whether it occurs at the top (apex), middle, or lower part of the anterior vaginal wall. The type of surgery will also depend on the type of damage that exists between supporting structures and the vaginal wall. One of the most common surgical repairs is colporrhaphy. This surgical procedure consists of making a longitudinal folding of the vaginal tissue, suturing it into place and creating a stronger point of resistance to the intruding bladder wall. Surgical mesh is sometimes used to strengthen the anterior vaginal wall. It has a 10–50% failure rate. In some cases a surgeon may choose to use surgical mesh to strengthen the repair. During surgery, the repair of the vaginal wall consists of folding over and then suturing the existing tissue between the vagina and bladder to strengthen it. This tightens the layers of tissue to promote the replacement of the pelvic organs into their normal place. The surgery also provides more support for the bladder.

Viscosity is measured with various types of viscometers and rheometers. Close temperature control of the fluid is essential to obtain accurate measurements, particularly in materials like lubricants, whose viscosity can double with a change of only 5 °C. A rheometer is used for fluids that cannot be defined by a single value of viscosity and therefore require more parameters to be set and measured than is the case for a viscometer. For some fluids, the viscosity is constant over a wide range of shear rates (Newtonian fluids). The fluids without a constant viscosity (non-Newtonian fluids) cannot be described by a single number. Non-Newtonian fluids exhibit a variety of different correlations between shear stress and shear rate. One of the most common instruments for measuring kinematic viscosity is the glass capillary viscometer. In coating industries, viscosity may be measured with a cup in which the efflux time is measured. There are several sorts of cup—such as the Zahn cup and the Ford viscosity cup—with the usage of each type varying mainly according to the industry. Also used in coatings, a Stormer viscometer employs load-based rotation to determine viscosity. The viscosity is reported in Krebs units (KU), which are unique to Stormer viscometers. Vibrating viscometers can also be used to measure viscosity. Resonant, or vibrational viscometers work by creating shear waves within the liquid. In this method, the sensor is submerged in the fluid and is made to resonate at a specific frequency.

L-DOPA to dopamine – a neurotransmitter L-Phenylalanine to phenethylamine – a trace amine which functions as a neuromodulator L-Tyrosine to tyramine – a trace amine neuromodulator L-Histidine to histamine – a neurotransmitter L-Tryptophan to tryptamine – a trace amine neuromodulator 5-HTP to serotonin (5-hydroxytryptamine) – a neurotransmitter However, some of these reactions do not seem to bear much or any biological significance. For example, histamine is biosynthesised strictly via the enzyme histidine decarboxylase in humans and other organisms.

Sources: en.wikipedia.org

Notes from published material

=== Injection === In order to inject ions from an external ion source, the field between the electrodes is first reduced. As ion packets are injected tangentially into the field, the electric field is increased by ramping the voltage on the inner electrode. Ions get squeezed towards the inner electrode until they reach the desired orbit inside the trap. At that moment ramping is stopped, the field becomes static, and detection can start. Each packet contains a multitude of ions of different velocities spread over a certain volume. These ions move with different rotational frequencies but with the same axial frequency. This means that ions of a specific mass-to-charge ratio spread into rings which oscillate along the inner spindle. Proof-of-principle of the technology was carried out using the direct injection of ions from an external laser desorption and ionization ion source. This method of injection works well with pulsed sources such as MALDI but cannot be interfaced to continuous ion sources like electrospray. All commercial Orbitrap mass spectrometers utilize a curved linear trap for ion injection (C-trap). By rapidly ramping down trapping RF voltages and applying DC gradients across the C-trap, ions can be bunched into short packets similar to those from the laser ion source. The C-trap is tightly integrated with the analyzer, injection optics and differential pumping.

Elongation factors are part of the mechanism that synthesizes new proteins through translation in the ribosome. Transfer RNAs (tRNAs) carry the individual amino acids that become integrated into a protein sequence, and have an anticodon for the specific amino acid that they are charged with. Messenger RNA (mRNA) carries the genetic information that encodes the primary structure of a protein, and contains codons that code for each amino acid. The ribosome creates the protein chain by following the mRNA code and integrating the amino acid of an aminoacyl-tRNA (also known as a charged tRNA) to the growing polypeptide chain. There are three sites on the ribosome for tRNA binding. These are the aminoacyl/acceptor site (abbreviated A), the peptidyl site (abbreviated P), and the exit site (abbreviated E). The P-site holds the tRNA connected to the polypeptide chain being synthesized, and the A-site is the binding site for a charged tRNA with an anticodon complementary to the mRNA codon associated with the site. After binding of a charged tRNA to the A-site, a peptide bond is formed between the growing polypeptide chain on the P-site tRNA and the amino acid of the A-site tRNA, and the entire polypeptide is transferred from the P-site tRNA to the A-site tRNA. Then, in a process catalyzed by the prokaryotic elongation factor EF-G (historically known as translocase), the coordinated translocation of the tRNAs and mRNA occurs, with the P-site tRNA moving to the E-site, where it dissociates from the ribosome, and the A-site tRNA moves to take its place in the P-site.

Cockrum incorporated Kane's alteration into his artwork for the story. At the time of his initial appearances, basic ideas about Wolverine's abilities and origins remained in development. While some sources indicate that Wein originally intended for Logan to be a mutated wolverine cub evolved to humanoid form by the High Evolutionary, Wein has denied this, suggesting that this may have been Cockrum's idea. In an article about the evolution of Wolverine included in Incredible Hulk and Wolverine (1986), a reprint of The Incredible Hulk #180–181, Cockrum confirmed that he considered having the High Evolutionary play a vital role in making Wolverine a human. In Wein's original conception, Wolverine was a young adult, and his claws were retractable and part of his gloves, with both made of adamantium. Romita said that he always envisioned the claws as retractable, explaining: "When I make a design, I want it to be practical and functional. I thought, 'If a man has claws like that, how does he scratch his nose or tie his shoelaces?'" Wein recollects that Cockrum first suggested that the claws were installed in Wolverine's forearms. Romita established Wolverine's short stature, deciding that he would be 5 feet, 3 inches (1.6 meters), reflecting the small size of wolverines.

Sources: en.wikipedia.org

Background from the literature

Bussolari of the MIT Lincoln Laboratory; the aerodynamicist was Mark Drela, with his XFOIL; in 1986, the team moves to Hanscom Field; the pilot Lois McCallin; after three to four hours of heavy exercise, the body's glucose is depleted; the first test aircraft had no ailerons, to save weight, resulting in a crash; a Hellenic Air Force C-130 arrives at Heraklion International Airport on 26 March 1988; three pilots train on Crete, eating around 7000 calories per day; the flight occurs on Saturday 23 April 1988, flying at around 18 knots; a gust of wind snapped the tail boom and wing on the beach. A US production, narrated by Andrew Sachs, produced by Mark Davis, made by WGBH. Shown on Nova on 22 November 1988 14 October Junk Mail, about direct marketing, increased by the affordability of computers, with Erik Larson.

When the particles either pass through each other without interaction or elastically repel during the collision, the gained kinetic energy (related to speed) begins to revert into potential energy, driving the collided particles apart. The decelerating particles will return to the initial distance and beyond into infinity, or stop and repeat the collision (oscillation takes place). This shows that the system, which loses no energy, does not combine (bind) into a solid object, parts of which oscillate at short distances. Therefore, to bind the particles, the kinetic energy gained due to the attraction must be dissipated by resistive force. Complex objects in collision ordinarily undergo inelastic collision, transforming some kinetic energy into internal energy (heat content, which is atomic movement), which is further radiated in the form of photons – the light and heat. Once the energy to escape the gravity is dissipated in the collision, the parts will oscillate at a closer, possibly atomic, distance, thus looking like one solid object. This lost energy, necessary to overcome the potential barrier to separate the objects, is the binding energy. If this binding energy were retained in the system as heat, its mass would not decrease, whereas binding energy lost from the system as heat radiation would itself have mass. It directly represents the "mass deficit" of the cold, bound system. Closely analogous considerations apply in chemical and nuclear reactions.

Usage within the Hindu and Buddhist cultures of the Indian subcontinent is common, with many street vendors in India openly selling products infused with cannabis, and traditional medical practitioners in Sri Lanka selling products infused with cannabis for recreational purposes and well as for religious celebrations. Indian laws criminalizing cannabis date back to the colonial period. India and Sri Lanka have allowed cannabis to be taken in the context of traditional culture for recreational/celebratory purposes and also for medicinal purposes. On 17 October 2015, Australian health minister Sussan Ley presented a new law that will allow the cultivation of cannabis for scientific research and medical trials on patients. On 17 October 2018, Canada legalized cannabis for recreational adult use making it the second country in the world to do so after Uruguay and the first G7 nation. This legalization comes with regulation similar to that of alcohol in Canada, age restrictions, limiting home production, distribution, consumption areas and sale times. Laws around use vary from province to province including age limits, retail structure, and growing at home. The Canadian Licensed Producer system aims to become the Gold Standard in the world for safe and secure cannabis production, including provisions for a robust craft cannabis industry where many expect opportunities for experimenting with different strains.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan II?

It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.

Is melanotan II an approved medicine?

No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.

What do published reports describe?

Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.

What conditions keep a lyophilized peptide stable?

Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.

Network